Open an account

Polaryx Therapeutics

PLYX · NASDAQ

$1.91−$0.01 (−0.52%)TodayMarket closed ·
Prev close $1.92

About PLYX

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. The company is headquartered in Paramus, New Jersey and currently employs 9 full-time employees. The company went IPO on 2026-02-02. Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.

Employees
9
Headquarters
Paramus, New Jersey
Listed
Feb 2, 2026
Sector
Health Care
Industry
Pharmaceuticals
Website
polaryx.com

PLYX key statistics

Market cap
95.21M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
32.43K
Volume
10.12K
Open price
$1.87
High today
$1.93
Low today
$1.83
52 Week high
$48.91
52 Week low
$1.84

Polaryx Therapeutics (PLYX) at a glance

Polaryx Therapeutics (PLYX) last traded at $1.91, with a market cap of 95.21M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.83 and $1.93. The current price is 4.4% above the day's low and 1.0% below its high.

Volume so far is 10.12K shares, below the average of 32.43K shares a day.

Over the past year Polaryx Therapeutics has ranged from $1.84 to $48.91, and now sits 0% of the way up that range.

The average analyst price target is $7.65, 300.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $7.65
Low
$6.06
Now
$1.91
High
$10.50

PLYX news

  • Avi Kapoor

    Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

  • Press releaseGlobe Newswire

    Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Polaryx Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.